PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (348)	1/27/2011 9:42:40 AM
From: John McCarthy	Read Replies (1) of 421

Hi Arthur Not sure if your still in but .... Alimera Sciences to Hold Conference Call to Discuss Results From the Final Readout of the FAME(TM) Study of ILUVIEN(R) ATLANTA, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM - News) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release data from the final readout of the FAME Study after the market close on Thursday, February 3, 2011. The FAME Study consists of two 36-month Phase 3 pivotal clinical trials to assess the safety and efficacy of ILUVIEN(R) in the treatment of diabetic macular edema (DME). finance.yahoo.com EDIT from a bad memory --- I think the 1st week in Feb was when Alimera had hoped to meet with the FDA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next